While the company added three more big pharma partners, this is not what shareholders prefer to hear as the company already has more than two dozen of these.

These partnerships are mostly in the pre-clinical phase and are unlikely to lead to near-time monetization.

For monetization, there are four near-time candidates, Voriconozale and Tacrolimus look to be the most certain candidates but PLUS (cannabis) and UNION (Niclosamide) are additional deal candidates.

A deal is necessary as cash levels are getting low, which might necessitate earlier partnering and forfeiting some future revenue.

But just one deal with upfront payments is likely to considerably improve their situation so the stock remains very interesting.

Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio.